Vietnam’s pharmaceutical industry reached $8.9 billion in sales, ranking second in Southeast Asia, yet the largest company, DHG, is valued at only $511 million, significantly below Indonesia’s Kalbe Farma at $3.9 billion. Vietnam’s market has around 250 manufacturers, mainly producing generic drugs with low profit margins, lacking innovation, whereas Kalbe invests heavily in R&D and has a diverse product range. However, both countries rely on imported raw materials. Vietnamese pharmaceutical firms faced various challenges in the first half of 2025, with some showing growth while others experienced sharp declines. Changes in pharmaceutical laws are expected to reform the industry, boost investment, and improve public access to quality medication.
Leave a Reply